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Objectives: To evaluate the in vitro activity of ceftolozane/tazobactam and comparators tested against
European isolates of Enterobacteriaceae and Pseudomonas aeruginosa from hospitalized patients with urinary
tract infection or intraabdominal infections.
Methods: A total of 6553 Gram-negative organisms (603 P. aeruginosa and 5950 Enterobacteriaceae) were con-
secutively collected from 41 hospitals located in 17 European countries plus Israel and Turkey. The organisms
were tested for susceptibility by broth microdilution methods and the results interpreted according to EUCAST
and CLSI breakpoint criteria.
Results: Ceftolozane/tazobactam [MIC50/90 0.25/1 mg/L; 93.5%/91.3% susceptible (S) (CLSI/EUCAST criteria)]
and meropenem [MIC50/900.06/0.06 mg/L; 98.1%/98.3% S (CLSI/EUCAST)] were the most active compounds
tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates, 1.9% were carbapenem resistant
(CRE), 15.2% exhibited an ESBL non-CRE phenotype, 14.6% were MDR, 2.2% were XDR and,0.1% were pan-drug
resistant (PDR). Whereas ceftolozane/tazobactam showed activity against ESBL non-CRE phenotype isolates
(MIC50/90 0.5/8 mg/L), it lacked useful activity against strains with a CRE (MIC50/90.32/>32 mg/L; 3.6% S) or PDR
(MIC50.32 mg/L; 0.0% S) phenotype. Ceftolozane/tazobactam was the most potent (MIC50/90 0.5/4 mg/L) b-lac-
tam agent tested against P. aeruginosa isolates, inhibiting 91.7% at an MIC of4 mg/L. P. aeruginosa exhibited
high rates of resistance to cefepime (20.6%), ceftazidime (23.1%), meropenem (9.0%) and piperacillin/tazobac-
tam (26.9%) (EUCAST criteria). Among these four P. aeruginosa resistant phenotypes, 61.3%–70.4% were sus-
ceptible to ceftolozane/tazobactam.
Conclusions: Ceftolozane/tazobactam was the most active b-lactam agent tested against P. aeruginosa and
demonstrated higher in vitro activity than currently available cephalosporins and piperacillin/tazobactam when
tested against Enterobacteriaceae.
Introduction
Healthcare-associated infections (HCAI) are important causes of
morbidity, mortality and excess medical costs worldwide.1 Over
half of all HCAI and associated antibiotic usage may be attributed
to the management of lower respiratory tract infections, urinary
tract infections (UTI) and intraabdominal infections (IAI).1,2
The spectrum of aetiological pathogens causing HCAIs is ever-
changing and varies from region to region and even from hospital
to hospital.1,3 From the 1970s through 2000, the spectrum of HCAI
pathogens shifted from Gram-negative bacilli (GNB) to include
both Gram-positive cocci (GPC) and Candida spp.1,3–5 More re-
cently, MDR GNB have become increasingly prevalent in the
hospital setting.6–9 Population-based surveillance of antibiotic
resistance in both Europe10 and the USA11 has documented
increasing resistance among GNB in a large proportion of facilities.
Prominent among the resistant species are ESBL- and
carbapenem-resistant Enterobacteriaceae (CRE) and MDR (resist-
ant to at least three antimicrobial classes) non-fermenters such as
Pseudomonas aeruginosa.6,9,12 Notably, this increase in resistance
among GNB reduces the likelihood of appropriate empiric
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therapy.13 It is now well established that delay in initial appropriate
therapy is associated with increased morbidity and mortality in pa-
tients with severe infections, particularly those caused by ESBL-
producing Enterobacteriaceae14 and P. aeruginosa.13,15
These findings underscore the continued importance of antibiotic
resistance surveillance and the need to assess the potential impact
of newly introduced and novel antibacterial agents targeting spe-
cific resistance phenotypes.16,17 Systematic and comprehensive
antibiotic resistance surveillance is essential to document the extent
of the resistance problem and to inform local, regional, national and
global efforts to combat the challenge of resistance.16
Ceftolozane/tazobactam is a novel antibacterial agent with
activity against P. aeruginosa, including antibiotic-resistant
strains, and other common GNB, including most ESBL-producing
Enterobacteriaceae strains.17–21 Ceftolozane/tazobactam is not
active against Acinetobacter spp., Stenotrophomonas maltophilia,
anaerobes, GPC or Enterobacteriaceae producing carbapene-
mases, metallo-b-lactamases and some AmpC b-lactamases.17,22
Ceftolozane/tazobactam has recently been approved for the treat-
ment of complicated IAIs and complicated UTIs.17 A Phase III
clinical trial of ceftolozane/tazobactam in the treatment of noso-
comial pneumonia is in progress.
In a previous antimicrobial resistance survey conducted in
Europe in 2011–12, we described the in vitro activity of ceftolozane/
tazobactam tested against isolates of Enterobacteriaceae and P.
aeruginosa from a variety of infection sites.19,20 In the present
study, we extend these observations and focus on the activity of
ceftolozane/tazobactam and selected b-lactam comparators
against 6553 isolates of P. aeruginosa (603 isolates) and
Enterobacteriaceae (5950 isolates) from patients with UTI or IAI
hospitalized at 41 European medical centres (19 countries) during
the period 2012–15. The analysis includes the activity of ceftolo-
zane/tazobactam against specific resistance phenotypes (e.g. ESBL
non-CRE phenotype and MDR strains of Enterobacteriaceae and
P. aeruginosa) as well as the frequency of resistance patterns
among the different European countries.
Materials and methods
Sampling sites and organisms
A total of 6553 GNB, including 5950 Enterobacteriaceae and 603
P. aeruginosa, were consecutively collected from 41 large academic
medical centres located in 17 European countries plus Turkey and Israel
by the Program to Assess Ceftolozane/Tazobactam Susceptibility
(PACTS). All organisms were isolated from hospitalized patients with
documented UTI or IAI between January 2012 and December 2015 and
only one isolate per patient infection episode was included in the sur-
veillance collection. Species identification was performed at each partic-
ipating medical centre and confirmed by the monitoring laboratory (JMI
Laboratories, North Liberty, IA, USA) using the VITEK 2 System
(bioMe´rieux, Hazelwood, MO, USA) or MALDI-TOF MS (Bruker, Billerica,
MA, USA), when necessary.
Antimicrobial susceptibility testing
MICs were determined using the reference CLSI broth microdilution method
(CLSI, 2015).23 Quality control (QC) and interpretation of results were per-
formed in accordance with CLSI M100-S26 and EUCAST 2016 guidelines
(CLSI, 201624; EUCAST, 201625). Escherichia coli, Klebsiella pneumoniae,
Klebsiella oxytoca and Proteus mirabilis were grouped as ‘ESBL phenotype’
based on the CLSI screening criteria for potential ESBL production—i.e. MIC
2 mg/L for ceftazidime and/or ceftriaxone and/or aztreonam.24 CRE were
defined as isolates displaying MIC 4 mg/L24 for imipenem (P. mirabilis and
indole-positive Proteeae were not included due to their intrinsically elevated
MIC values) and/or meropenem and/or doripenem. MDR, XDR and pan-drug-
resistant (PDR) Enterobacteriaceae isolates were classified according to re-
cently recommended guidelines26 and using the following antimicrobial class
representative agents: ceftriaxone, meropenem, piperacillin/tazobactam,
levofloxacin, gentamicin, tigecycline and colistin (seven classes). Results for
doripenem, levofloxacin, gentamicin, tigecycline and colistin were used to de-
termine MDR, XDR and PDR phenotypes and are not reported individually.
Classifications were based on the following recommended parameters:
MDR"non-susceptible (NS; CLSI/EUCAST breakpoints) to at least three anti-
microbial classes; XDR" susceptible (S) to two or fewer antimicrobial classes;
and PDR"NS to all antimicrobial classes.26 Classifications of isolates as resist-
ant (R), NS or S to each antimicrobial agent were based on EUCAST break-
points for tigecycline and colistin and CLSI breakpoints for all other agents.
Isolates of P. aeruginosa were classified as ceftolozane/tazobactam-NS
(MIC.4 mg/L), ceftazidime-NS (MIC.8 mg/L), piperacillin/tazobactam-NS
(MIC.16 mg/L) and meropenem-NS (MIC.2 mg/L).
Results
Among the 6553 isolates tested, there were 5950
Enterobacteriaceae isolates (including 3460 E. coli isolates, 1112
Klebsiella spp. isolates, 432 Enterobacter spp. isolates, 256
Citrobacter spp. isolates, 368 P. mirabilis isolates, 237 indole-
positive Proteeae isolates and 77 Serratia spp. isolates) and 603
P. aeruginosa isolates (Table 1).
Overall activity of ceftolozane/tazobactam
During the years 2012–15, ceftolozane/tazobactam maintained a
consistent and potent level of activity against the UTI and IAI tar-
get pathogens from the European study sites (Table 1). Among the
Enterobacteriaceae isolates tested, 1.9% were CRE, 15.2% ex-
hibited an ESBL non-CRE phenotype, 14.6% were MDR, 2.2% were
XDR and,0.1% were PDR (Table 1). An ESBL non-CRE phenotype
was observed in 16.2% of E. coli and 30.5% of K. pneumoniae iso-
lates. An ESBL phenotype was detected in 18.4% of K. oxytoca and
8.7% of P. mirabilis isolates. Important resistant phenotypes
among the P. aeruginosa isolates included ceftazidime-NS
(23.1%), meropenem-NS (20.9%), cefepime-NS (20.6%) and
piperacillin/tazobactam-NS (26.9%) (Table 1).
Against Enterobacteriaceae isolates, ceftolozane/tazobactam
MIC values ranged from 0.015 to.32 mg/L, and 91.3%/93.5%
of the tested isolates were inhibited at an MIC value
of1/2 mg/L (EUCAST/CLSI susceptible breakpoint) (Table 1).
Whereas ceftolozane/tazobactam showed good activity against
ESBL non-CRE phenotype isolates of Enterobacteriaceae (MIC50/90
0.5/8 mg/L), it lacked useful activity against isolates with a CRE
(MIC50/90.32/>32 mg/L; 3.6% S) or PDR (MIC50.32 mg/L; 0.0% S)
phenotype.
Ceftolozane/tazobactam MIC values ranged from 0.12
to.32 mg/L against isolates of P. aeruginosa, and 91.7% of the
tested isolates were inhibited at an MIC value of4 mg/L (CLSI
and EUCAST breakpoint). Among the four resistant phenotypes,
61.3%–70.4% were susceptible to ceftolozane/tazobactam
(Table 1).
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Activities of ceftolozane/tazobactam and comparators
against Enterobacteriaceae
Ceftolozane/tazobactam (MIC50/90 0.25/1 mg/L) inhibited 93.5% of
the 5950 Enterobacteriaceae isolates tested at2 mg/L and 95.0%
of the isolates at4 mg/L (CLSI susceptible and intermediate break-
point criteria, respectively) (Table 1). Enterobacteriaceae isolates
displayed susceptibility rates to other b-lactam agents ranging from
84.4%/80.2% for ceftazidime, 84.9%/83.0% for cefepime, 89.1%/
85.1% for piperacillin/tazobactam and 98.1%/98.3% for merope-
nem using CLSI/EUCAST breakpoints. Using MIC90 values, ceftolo-
zane/tazobactam was 16-fold more active than cefepime and
ceftazidime (both MIC90 16 mg/L), was 32-fold more potent than
piperacillin/tazobactam (MIC90 32 mg/L), and was second in po-
tency to meropenem (MIC900.06 mg/L) (Table 2). Against 906
(15.2%) ESBL non-CRE phenotype Enterobacteriaceae isolates,
meropenem [MIC50/900.06/0.06 mg/L; 99.2%/100.0% S (CLSI/
EUCAST criteria)] and ceftolozane/tazobactam (MIC50/90 0.5/8 mg/L;
82.8%/74.9% S) were the only agents to retain clinically useful
activity of the antimicrobials assessed (Table 2).
In total 3460 E. coli isolates were evaluated, 98.8%/98.0%
of which were susceptible to ceftolozane/tazobactam (MIC50/90
0.25/0.5 mg/L) by CLSI/EUCAST interpretive guidelines. Meropenem
[MIC50/900.06/0.06 mg/L; 100.0%/100.0% S (CLSI/EUCAST)]
and piperacillin/tazobactam (MIC50/90 2/8 mg/L; 94.0%/90.5% S)
showed good activity against E. coli, followed by cefepime
(MIC50/900.5/8 mg/L; 87.5%/85.9% S) and ceftazidime (MIC50/90
0.12/8 mg/L; 89.9%/85.4% S) (Table 2). Among ESBL non-CRE
phenotype isolates of E. coli (16.2%), resistance rates to cefepime,
ceftazidime and piperacillin/tazobactam were elevated (Table 2).
Meropenem retained potent activity (MIC50/900.06/0.06 mg/L;
100.0% S) against ESBL non-CRE phenotype isolates of E. coli.
Ceftolozane/tazobactam inhibited 92.7% of the ESBL non-CRE
phenotype E. coli isolates at2 mg/L (Tables 1 and 2).
Ceftolozane/tazobactam showed potent activity against
non-ESBL phenotype isolates of K. pneumoniae [MIC50/90
0.25/0.5 mg/L; highest MIC 2 mg/L (data not shown)] and retained
activity against many ESBL non-CRE phenotype isolates (MIC50/90
1/>32 mg/L; 65.4%/55.4% S) (Tables 1 and 2). Among the
b-lactam comparator agents tested, only meropenem was more
active than ceftolozane/tazobactam against Klebsiella species irre-
spective of the resistant phenotype (Table 2). Ceftolozane/tazo-
bactam was also active against other frequently isolated
Enterobacteriaceae including K. oxytoca (MIC50/90 0.25/2 mg/L),
Enterobacter spp. (MIC50/90 0.5/8 mg/L), Citrobacter spp. (MIC50/90
0.25/8 mg/L), P. mirabilis (MIC50/90 0.5/0.5 mg/L), indole-positive
Proteeae (MIC50/90 0.25/1 mg/L) and Serratia spp. (MIC50/90
0.5/2 mg/L) (Tables 1 and 2).
Previously (2012) we have shown that among European isolates
of Enterobacteriaceae from patients with pneumonia, the rates of
MDR and XDR phenotypes varied markedly from country to coun-
try.19 As seen in Table 3, resistance rates among Enterobacteriaceae
causing either UTI or IAI also show considerable variability among
the European nations evaluated. The occurrence of CRE, MDR and
XDR Enterobacteriaceae was highest in Poland (29.9%, 72.2% and
32.0%, respectively) and lowest in Austria (0.0%, 3.1% and 0.0%, re-
spectively), Denmark (0.0%, 4.2% and 0.0%, respectively), Finland
(0.0%, 1.9% and 0.0%, respectively) and Switzerland (0.0%, 2.1%
and 0.0%, respectively) (Table 3). The highest rates of ESBL non-CRE
phenotype Enterobacteriaceae were found in isolates from Poland
(32.5%) and Turkey (36.2%) and the lowest were in isolates from
Austria (0.0%), Finland (1.9%) and Switzerland (2.1%). The fre-
quency of CRE was,1.0% in 14 of the 19 countries contributing to
the survey. Among the five major Western European countries
(France, Germany, Italy, Spain and the UK), the occurrence of MDR
Enterobacteriaceae was higher in Italy (18.4%) when compared
with the other four countries (6.4%–12.6%) (Table 3). These data
are comparable to those reported in 2012 for respiratory tract iso-
lates of Enterobacteriaceae from Europe.19
Activities of ceftolozane/tazobactam and comparators
against P. aeruginosa
Ceftolozane/tazobactam was the most potent (MIC50/90
0.5/4 mg/L) b-lactam agent tested against 603 P. aeruginosa iso-
lates, inhibiting 91.7% at a MIC of4 mg/L (Tables 1 and 2). Based
on the MIC90 value, ceftolozane/tazobactam was 2-fold more ac-
tive than meropenem (MIC90 8 mg/L), 4-fold more active than
cefepime (MIC90 16 mg/L), 8-fold more active than ceftazidime
(MIC90 32 mg/L) and at least 32-fold more active than piperacillin/
tazobactam (MIC90.64 mg/L) (Table 2). Overall susceptibility rates
(by CLSI/EUCAST criteria; Table 2) for cefepime (79.4%/79.4%), cef-
tazidime (76.9%/76.9%), meropenem (79.1%/79.1%) and pipera-
cillin/tazobactam (73.1%/73.1%) were all below that of
ceftolozane/tazobactam at4 mg/L (91.7%/91.7%; Table 2).
Ceftolozane/tazobactam retained moderate activity against
isolates of P. aeruginosa that were NS to the other antipseudomo-
nal b-lactam agents (Table 2): ceftazidime-NS (65.5% susceptible),
meropenem-NS (65.9%), cefepime-NS (61.3%) and piperacillin/
tazobactam-NS (70.4%). None of the other b-lactam agents in-
hibited.40.7% of these resistant phenotype isolates.
As observed in 2011–12,20 P. aeruginosa susceptibility to anti-
pseudomonal b-lactams varied markedly among the European
nations that participated in the survey (Table 4). The lowest sus-
ceptibility rates for ceftazidime and meropenem were observed in
Poland (46.9% and 34.4%, respectively) and Portugal (52.6%
and 44.7%). Decreased susceptibility rates to ceftazidime and
meropenem were also noted in Greece (61.1% for both com-
pounds), Israel (69.2% and 76.9%, respectively), Italy (73.3% and
78.7%), Russia (20.0% for ceftazidime) and Turkey (63.6%
and 70.5%). Ceftolozane/tazobactam activity was also compro-
mised when tested against P. aeruginosa isolates from Greece
(61.1% susceptible), Poland (75.0%), Portugal (63.2%) and Russia
(60.0%), but it provided 100.0% coverage against isolates from 11
of the 19 countries (Table 4). P. aeruginosa isolates from the five
most populous Western European countries (i.e. France, Germany,
Italy, Spain and the UK; 332 isolates) were more susceptible to cef-
tolozane/tazobactam (96.4%), ceftazidime (81.9%) and merope-
nem (84.9%) than isolates from 6 of the remaining 14 countries
(Table 4).
Discussion
The results of the present study both confirm and extend those
previously reported concerning the in vitro activity of ceftolozane/
tazobactam against European isolates of Enterobacteriaceae and
P. aeruginosa.19–21 Ceftolozane/tazobactam was the most active of
the tested b-lactam agents against P. aeruginosa and was second
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Table 2. Activity of ceftolozane/tazobactam and comparator antimicrobial agents when tested against Enterobacteriaceae and P. aeruginosa from
European hospitals (2012–15)
Organism (no. tested)/antimicrobial agent
MIC (mg/L) %S/%I/%R
50% 90% CLSI EUCAST
Enterobacteriaceae (5950)
ceftolozane/tazobactam 0.25 1 93.5/1.5/5.0 91.3/–/8.7
cefepime 0.5 16 84.9/3.6/11.4 83.0/3.8/13.2
ceftazidime 0.25 16 84.4/2.7/12.8 80.2/4.2/15.6
meropenem 0.06 0.06 98.1/0.2/1.7 98.3/0.8/1.0
piperacillin/tazobactam 2 32 89.1/4.1/6.8 85.1/4.0/10.9
ESBL non-CRE phenotype (906)
ceftolozane/tazobactam 0.5 8 82.8/6.0/11.3 74.9/–/25.1
cefepime 16 .16 23.1/18.8/58.1 15.1/17.1/67.8
ceftazidime 16 .32 33.8/14.7/51.5 10.5/23.3/66.2
meropenem 0.06 0.06 99.2/0.8/0.0 100.0/0.0/0.0
piperacillin/tazobactam 8 .64 70.8/10.8/18.4 57.2/13.6/29.2
E. coli (3460)
ceftolozane/tazobactam 0.25 0.5 98.8/0.3/0.9 98.0/–/2.0
cefepime 0.5 8 87.5/3.1/9.3 85.9/3.3/10.9
ceftazidime 0.12 8 89.9/2.5/7.7 85.4/4.4/10.1
meropenem 0.06 0.06 100.0/0.0/0.0 100.0/0.0/0.0
piperacillin/tazobactam 2 8 94.0/2.9/3.2 90.5/3.4/6.0
ESBL non-CRE phenotype (559)
ceftolozane/tazobactam 0.5 2 92.7/2.0/5.4 87.8/–/12.2
cefepime 16 .16 23.2/18.6/58.2 15.0/17.5/67.6
ceftazidime 8 .32 37.2/15.4/47.4 9.8/27.4/62.8
meropenem 0.06 0.06 100.0/0.0/0.0 100.0/0.0/0.0
piperacillin/tazobactam 8 64 81.1/9.3/9.5 66.6/14.5/18.9
Klebsiella spp. (1112)
ceftolozane/tazobactam 0.25 32 82.1/3.4/14.5 78.2/–/21.8
cefepime 0.5 .16 68.8/5.6/25.6 67.1/4.2/28.7
ceftazidime 0.25 .32 70.3/4.0/25.6 66.5/3.9/29.7
meropenem 0.06 0.5 91.1/0.9/8.0 92.0/3.1/4.9
piperacillin/tazobactam 4 .64 74.8/5.4/19.8 69.3/5.4/25.2
K. pneumoniae (917)
ceftolozane/tazobactam 0.25 .32 79.3/3.7/17.0 75.8/–/24.2
cefepime 0.5 .16 63.4/6.0/30.6 62.4/3.6/34.0
ceftazidime 0.25 .32 64.6/4.7/30.8 60.3/4.3/35.4
meropenem 0.06 2 89.2/1.1/9.7 90.3/3.7/6.0
piperacillin/tazobactam 4 .64 73.2/6.4/20.4 66.7/6.5/26.8
ESBL phenotype (373)
ceftolozane/tazobactam 4 .32 49.1/9.1/41.8 41.6/–/58.4
cefepime .16 .16 9.9/14.7/75.3 7.8/8.6/83.6
ceftazidime 32 .32 12.9/11.5/75.6 2.4/10.5/87.1
meropenem 0.06 .8 73.5/2.7/23.9 76.1/9.1/14.7
piperacillin/tazobactam 64 .64 40.7/11.9/47.4 30.1/10.6/59.3
ESBL non-CRE phenotype (280)
ceftolozane/tazobactam 1 .32 65.4/12.1/22.5 55.4/–/44.6
cefepime .16 .16 13.2/19.6/67.1 10.4/11.4/78.2
ceftazidime 16 .32 17.1/15.4/67.5 3.2/13.9/82.9
meropenem 0.06 0.12 97.5/2.5/0.0 100.0/0.0/0.0
piperacillin/tazobactam 16 .64 54.3/15.9/29.7 40.2/14.1/45.7
K. oxytoca (190)
ceftolozane/tazobactam 0.25 2 95.3/2.1/2.6 89.5/–/10.5
Continued
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Table 2 Continued
Organism (no. tested)/antimicrobial agent
MIC (mg/L) %S/%I/%R
50% 90% CLSI EUCAST
cefepime 0.5 2 94.2/3.7/2.1 88.9/7.4/3.7
ceftazidime 0.12 1 97.4/1.1/1.6 95.3/2.1/2.6
meropenem 0.06 0.06 100.0/0.0/0.0 100.0/0.0/0.0
piperacillin/tazobactam 2 64 82.0/1.1/16.9 81.5/0.5/18.0
ESBL phenotype (35)
ceftolozane/tazobactam 2 8 74.3/11.4/14.3 42.9/–/57.1
cefepime 2 16 68.6/20.0/11.4 40.0/40.0/20.0
ceftazidime 1 8 85.7/5.7/8.6 74.3/11.4/14.3
meropenem 0.06 0.06 100.0/0.0/0.0 100.0/0.0/0.0
piperacillin/tazobactam .64 .64 8.6/2.9/88.6 8.6/0.0/91.4
Enterobacter spp. (432)
ceftolozane/tazobactam 0.5 8 78.0/6.5/15.5 69.7/–/30.3
cefepime 0.5 16 80.6/7.6/11.8 76.4/8.8/14.8
ceftazidime 0.5 .32 62.3/3.9/33.8 58.1/4.2/37.7
meropenem 0.06 0.12 97.5/0.5/2.1 97.9/1.9/0.2
piperacillin/tazobactam 4 .64 73.3/15.1/11.6 65.0/8.4/26.7
E. cloacae (278)
ceftolozane/tazobactam 0.5 16 76.6/5.0/18.3 70.1/–/29.9
cefepime 0.5 16 79.1/10.1/10.8 74.8/10.8/14.4
ceftazidime 0.5 .32 65.1/2.5/32.4 61.5/3.6/34.9
meropenem 0.06 0.12 97.5/0.7/1.8 98.2/1.4/0.4
piperacillin/tazobactam 4 .64 75.1/11.2/13.7 67.9/7.2/24.9
E. aerogenes (105)
ceftolozane/tazobactam 0.5 4 82.9/9.5/7.6 72.4/–/27.6
cefepime 0.5 1 93.3/1.9/4.8 91.4/3.8/4.8
ceftazidime 0.5 .32 62.9/6.7/30.5 58.1/4.8/37.1
meropenem 0.06 0.06 99.0/0.0/1.0 99.0/1.0/0.0
piperacillin/tazobactam 4 64 71.4/23.8/4.8 63.8/7.6/28.6
Citrobacter spp. (256)
ceftolozane/tazobactam 0.25 8 87.1/2.0/10.9 86.7/–/13.3
cefepime 0.5 1 97.7/0.8/1.6 94.5/3.9/1.6
ceftazidime 0.25 .32 83.2/1.6/15.2 82.0/1.2/16.8
meropenem 0.06 0.06 98.8/0.4/0.8 99.2/0.4/0.4
piperacillin/tazobactam 2 64 87.1/4.7/8.2 83.6/3.5/12.9
C. koseri (101)
ceftolozane/tazobactam 0.25 0.5 100.0/0.0/0.0 100.0/0.0/0.0
cefepime 0.5 0.5 100.0/0.0/0.0 100.0/0.0/0.0
ceftazidime 0.12 0.25 100.0/0.0/0.0 100.0/0.0/0.0
meropenem 0.06 0.06 100.0/0.0/0.0 100.0/0.0/0.0
piperacillin/tazobactam 2 8 100.0/0.0/0.0 98.0/2.0/0.0
C. freundii (111)
ceftolozane/tazobactam 0.25 8 79.3/2.7/18.0 78.4/–/21.6
cefepime 0.5 1 97.3/0.9/1.8 91.9/6.3/1.8
ceftazidime 0.5 .32 73.0/2.7/24.3 70.3/2.7/27.0
meropenem 0.06 0.06 99.1/0.0/0.9 99.1/0.0/0.9
piperacillin/tazobactam 4 .64 78.4/7.2/14.4 73.9/4.5/21.6
P. mirabilis (368)
ceftolozane/tazobactam 0.5 0.5 97.3/1.6/1.1 95.7/–/4.3
cefepime 0.5 0.5 96.2/1.4/2.4 94.0/3.0/3.0
ceftazidime 0.06 0.12 96.7/0.5/2.7 92.7/4.1/3.3
meropenem 0.06 0.12 100.0/0.0/0.0 100.0/0.0/0.0
Continued
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Table 2 Continued
Organism (no. tested)/antimicrobial agent
MIC (mg/L) %S/%I/%R
50% 90% CLSI EUCAST
piperacillin/tazobactam 0.5 1 100.0/0.0/0.0 99.2/0.8/0.0
ESBL phenotype (32)
ceftolozane/tazobactam 1 8 71.9/15.6/12.5 56.2/–/43.8
cefepime 2 .16 56.2/15.6/28.1 31.2/34.4/34.4
ceftazidime 4 32 62.5/6.2/31.2 15.6/46.9/37.5
meropenem 0.06 0.12 100.0/0.0/0.0 100.0/0.0/0.0
piperacillin/tazobactam 1 8 100.0/0.0/0.0 93.8/6.2/0.0
Indole-positive Proteeae (237)
ceftolozane/tazobactam 0.25 1 97.5/0.0/2.5 94.9/–/5.1
cefepime 0.5 0.5 95.8/1.7/2.5 94.9/2.1/3.0
ceftazidime 0.12 8 89.8/3.8/6.4 84.7/5.1/10.2
meropenem 0.06 0.12 99.6/0.0/0.4 99.6/0.0/0.4
piperacillin/tazobactam 0.5 2 97.5/2.1/0.4 96.2/1.3/2.5
Serratia spp. (77)
ceftolozane/tazobactam 0.5 2 98.7/0.0/1.3 88.3/–/11.7
cefepime 0.5 0.5 97.4/2.6/0.0 94.8/5.2/0.0
ceftazidime 0.25 0.5 97.4/0.0/2.6 94.8/2.6/2.6
meropenem 0.06 0.12 97.4/0.0/2.6 97.4/2.6/0.0
piperacillin/tazobactam 2 16 90.9/6.5/2.6 85.7/5.2/9.1
P. aeruginosa (603)
ceftolozane/tazobactam 0.5 4 91.7/1.7/6.6 91.7/–/8.3
cefepime 2 16 79.4/11.1/9.5 79.4/–/20.6
ceftazidime 2 32 76.9/5.5/17.6 76.9/–/23.1
meropenem 0.5 8 79.1/6.3/14.6 79.1/12.0/9.0
piperacillin/tazobactam 4 .64 73.1/12.8/14.1 73.1/–/26.9
Ceftazidime-NS (139)
ceftolozane/tazobactam 4 .32 65.5/6.5/28.1 65.5/–/34.5
cefepime 16 .16 23.7/39.6/36.7 23.7/–/76.3
ceftazidime 32 .32 0.0/23.7/76.3 0.0/–/100.0
meropenem 4 .8 39.6/10.8/49.6 39.6/28.1/32.4
piperacillin/tazobactam .64 .64 8.6/37.4/54.0 8.6/–/91.4
Meropenem-NS (126)
ceftolozane/tazobactam 2 .32 65.9/4.8/29.4 65.9/–/34.1
cefepime 16 .16 32.5/33.3/34.1 32.5/–/67.5
ceftazidime 32 .32 33.3/12.7/54.0 33.3/–/66.7
meropenem 8 .8 0.0/30.2/69.8 0.0/57.1/42.9
piperacillin/tazobactam 64 .64 23.8/31.0/45.2 23.8/–/76.2
Cefepime-NS (124)
ceftolozane/tazobactam 4 .32 61.3/8.1/30.6 61.3/–/38.7
cefepime 16 .16 0.0/54.0/46.0 0.0/–/100.0
ceftazidime 32 .32 14.5/8.9/76.6 14.5/–/85.5
meropenem 8 .8 31.5/10.5/58.1 31.5/32.3/36.3
piperacillin/tazobactam .64 .64 4.0/29.1/66.9 4.0/–/96.0
Piperacillin/tazobactam-NS (162)
ceftolozane/tazobactam 2 .32 70.4/6.2/23.5 70.4/–/29.6
cefepime 16 .16 26.5/38.9/34.6 26.5/–/73.5
ceftazidime 32 .32 21.6/13.0/65.4 21.6/–/78.4
meropenem 4 .8 40.7/13.6/45.7 40.7/30.2/29.0
piperacillin/tazobactam .64 .64 0.0/47.5/52.5 0.0/–/100.0
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to meropenem against Enterobacteriaceae. Whereas ceftolozane/
tazobactam had little activity against CRE, XDR or PDR isolates of
Enterobacteriaceae, it retained activity against most ESBL non-CRE
phenotype isolates, second only to meropenem. Likewise, ceftolo-
zane/tazobactam was more active than the other antipseudomo-
nal b-lactam agents tested against isolates of P. aeruginosa that
were NS to cefepime, meropenem or piperacillin/tazobactam.
In agreement with previous surveys,18–21 we found a great deal
of variation in resistance rates to ceftazidime and meropenem
with higher rates of resistance among European countries in the
southern (Greece and Portugal) and eastern (Poland) countries
versus northern countries (such as Germany, Ireland, Sweden
and the UK). This pertains to both Enterobacteriaceae and
P. aeruginosa (Tables 3 and 4) and has been shown to correlate
with regional differences in b-lactamase production.20
Whereas the spread of CRE is a major concern in Europe, the
prevalence is variable.20,27 Higher prevalence rates of CRE have
been reported in Greece, Italy, Turkey and Israel, with lower rates
in the northern nations.20,27 Our results confirm these observations
with CRE rates exceeding 1% in Greece (5.4%), Israel (1.2%), Italy
(3.8%), Poland (29.9%) and Turkey (1.8%) (Table 3). Notably, CRE
were not identified in 7 of the 19 countries participating in the sur-
vey. High and variable rates of ESBL non-CRE phenotype and MDR
Enterobacteriaceae are consistent with those previously reported
by Farrell et al.,19 Sader et al.20 and Canton et al.27
In summary, these data for ceftolozane/tazobactam collected in
2012–15 from 41 medical centres in 17 European countries plus
Israel and Turkey demonstrated sustained potency and spectrum
against Enterobacteriaceae and P. aeruginosa when compared to
previous European studies.20,21 These data suggest that ceftolo-
zane/tazobactam may be an important treatment option for UTI
and IAI caused by both wild-type and MDR strains of P. aeruginosa
and Enterobacteriaceae.17 One of the more important aspects of
this survey is the confirmation of extensive variation in antibiotic-
resistant phenotypes of GNB across Europe. This finding emphasizes
the need for ongoing surveillance and application of antimicrobial
stewardship to prevent the further spread of b-lactam resistance.16
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